Title:
ヒト骨髄由来内皮前駆細胞の同定、及び虚血性傷害後の心筋細胞の機能を改善するためのヒト骨髄由来内皮前駆細胞の使用
Document Type and Number:
Japanese Patent JP2004509847
Kind Code:
A
Abstract:
The present invention provides a method of stimulating vasculogenesis of myocardial infarct damaged tissue in a subject comprising: (a) removing stem cells from a location in the subject; (b) recovering endothelial progenitor cells in the stem cells; (c) introducing the endothelial progenitor cells from step (b) into a different location in the subject such that the precursors migrate to and stimulate revascularization of the tissue. The stem cells may be removed directly or by mobilization. The endothelial progenitor cells may be expanded before introduction into the subject. The present invention further provides a method of inducing angiogenesis in peri-infarct tissue. The present invention further provides a method of selectively increasing the trafficking of human bone marrow-derived endothelial cell precursors to the site of tissue damaged by ischemic injury which comprises: (a) administering endothelial progenitor cells to a subject; (b) administering chemokines to the subject so as to thereby attract endothelial cell precursors to the ischemic tissue. The present invention provides a method of stimulating vasculogenesis or angiogenesis of myocardial infarct damaged tissue in a subject comprising injecting allogeneic stem cells into a subject. The present invention further provides a method of improving myocardial function in a subject that has suffered a myocardial infarct comprising any of the instant methods. The present invention further provides a method of improving myocardial function in a subject that has suffered a myocardial infarct comprising injecting G-CSF or anti-CXCR4 antibody into the subject in order to mobilize endothelial progenitor cells.
Inventors:
Itishu, Silviu
Application Number:
JP2002501968A
Publication Date:
April 02, 2004
Filing Date:
June 05, 2001
Export Citation:
Assignee:
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
International Classes:
C12N15/09; A61K35/12; A61K35/44; A61K38/00; A61K38/19; A61K38/22; A61K38/27; A61K39/395; A61K45/00; A61K48/00; A61P3/10; A61P7/02; A61P7/04; A61P9/04; A61P9/08; A61P9/10; A61P25/28; A61P35/00; A61P43/00; C07K16/24; C07K16/28; C12N5/074; C12Q1/68; A61K39/00; (IPC1-7): A61K35/12; A61K38/00; A61K38/22; A61K38/27; A61K39/395; A61K45/00; A61K48/00; A61P3/10; A61P7/02; A61P7/04; A61P9/04; A61P9/08; A61P9/10; A61P25/28; A61P35/00; A61P43/00; C12N5/06; C12Q1/68
Domestic Patent References:
| JPH08231595A | 1996-09-10 | |||
| JPH06287167A | 1994-10-11 |
Foreign References:
| WO1999045775A1 | 1999-09-16 | |||
| WO1998019712A1 | 1998-05-14 | |||
| WO1999018460A1 | 1999-04-15 |
Other References:
JPN6011033490; Ｓｃｉｅｎｃｅ ｖｏｌ．２５７， ｎｏ．４, 1992, ｐ．１４０１-１４０３
JPN6011033491; Ｃｅｌｌ Ｐｒｏｌｉｆｅｒａｔｉｏｎ ｖｏｌ．２９, 1996, ｐ．３１５-３２３
JPN6012020170; Ｂｌｏｏｄ ｖｏｌ．９５， ｎｏ．３, 2000, ｐ．９５２-９５８
JPN6013004822; Ｍｅｄｉｚｉｎｉｓｃｈｅ Ｋｌｉｎｉｋ ｖｏｌ．９４， ｎｏ．４, 1999, ｐ．１９３-２０１
JPN6011033491; Ｃｅｌｌ Ｐｒｏｌｉｆｅｒａｔｉｏｎ ｖｏｌ．２９, 1996, ｐ．３１５-３２３
JPN6012020170; Ｂｌｏｏｄ ｖｏｌ．９５， ｎｏ．３, 2000, ｐ．９５２-９５８
JPN6013004822; Ｍｅｄｉｚｉｎｉｓｃｈｅ Ｋｌｉｎｉｋ ｖｏｌ．９４， ｎｏ．４, 1999, ｐ．１９３-２０１
Attorney, Agent or Firm:
Takehiko Suzue
Sadao Muramatsu
Ryo Hashimoto
Toshio Shirane
Sadao Muramatsu
Ryo Hashimoto
Toshio Shirane